読み込み中
XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to advancing and bringing to market medical treatments targeting a range of conditions, including chronic kidney ailments, diabetes, insulin resistance, metabolic syndrome, diabetic nephropathy, and various infections. Their pipeline includes XRx-008, a late-stage clinical program designed to address autosomal dominant polycystic kidney disease (ADPKD). Another key candidate is XRx-101, an agent aimed at reducing uric acid levels in COVID-19 patients, with the goal of mitigating acute kidney injury and related complications. Furthermore, they are developing XRx-221, a series of xanthine oxidase inhibitors intended for the management of diabetic nephropathy. XORTX also collaborates with the Icahn School of Medicine on research investigating acute kidney injury and hyperuricemia among hospitalized COVID-19 patients. The company's operations are headquartered in Vancouver, Canada.
前日終値
$1.41
−$0.44 · -23.78%
日中の時刻はETです。市場データは遅延する場合があります。
XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to advancing and bringing to market medical treatments targeting a range of conditions, including chronic kidney ailments, diabetes, insulin resistance, metabolic syndrome, diabetic nephropathy, and various infections. Their pipeline includes XRx-008, a late-stage clinical program designed to address autosomal dominant polycystic kidney disease (ADPKD). Another key candidate is XRx-101, an agent aimed at reducing uric acid levels in COVID-19 patients, with the goal of mitigating acute kidney injury and related complications. Furthermore, they are developing XRx-221, a series of xanthine oxidase inhibitors intended for the management of diabetic nephropathy. XORTX also collaborates with the Icahn School of Medicine on research investigating acute kidney injury and hyperuricemia among hospitalized COVID-19 patients. The company's operations are headquartered in Vancouver, Canada.
日中レンジ
現在 $1.41
52週レンジ
現在 $1.41
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
28
割高
センチメント
58
まちまち
リスク
51
やや高いリスク
モメンタム
25
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to advancing and bringing to market medical treatments targeting a range of conditions, including chronic kidney ailments, diabetes, insulin resistance, metabolic syndrome, diabetic nephropathy, and various infections. Their pipeline includes XRx-008, a late-stage clinical program designed to address autosomal dominant polycystic kidney disease (ADPKD). Another key candidate is XRx-101, an agent aimed at reducing uric acid levels in COVID-19 patients, with the goal of mitigating acute kidney injury and related complications. Furthermore, they are developing XRx-221, a series of xanthine oxidase inhibitors intended for the management of diabetic nephropathy. XORTX also collaborates with the Icahn School of Medicine on research investigating acute kidney injury and hyperuricemia among hospitalized COVID-19 patients. The company's operations are headquartered in Vancouver, Canada.
日中レンジ
現在 $1.41
52週レンジ
現在 $1.41
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | — | 11.16万 USD | — | — | 1.8万 USD |
| 粗利益 | — | −11.16万 USD | — | — | −1.8万 USD |
| 研究開発 | 57.49万 USD | 17.5万 USD | 241.87万 USD | 915.52万 USD | 85.68万 USD |
| 販売・一般管理 | 183.17万 USD | 363.39万 USD | 222.77万 USD | 327.85万 USD | 204.61万 USD |
| 営業費用 | 325.6万 USD | 380.89万 USD | 604.6万 USD | 1243.36万 USD | 365.93万 USD |
| 受取利息 | 4.19万 USD | 11.61万 USD | 25.35万 USD | 14.03万 USD | — |
| 支払利息 | — | — | — | — | 5628 USD |
| 減価償却費と償却費 | 11.21万 USD | 11.73万 USD | 13.97万 USD | 7.49万 USD | 1.76万 USD |
| 営業利益 | −325.6万 USD | −392.06万 USD | −604.6万 USD | −1243.36万 USD | −367.73万 USD |
| 純利益 | −265.63万 USD | −315.43万 USD | −215.81万 USD | −1045.1万 USD | −166.49万 USD |
会社概要が更新されました 2026年10月11日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2026年4月6日 | 1:5 | — | — |
株式分割 | 2023年11月14日 | 1:9 | — | — |
株式分割 | 2021年9月23日 | 1:12 | — | — |
発効済み 2026年4月6日
1:5
発効済み 2023年11月14日
1:9
発効済み 2021年9月23日
1:12
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
